Highlights of weekly biotech stock moves

Allos Therapeutics Inc. (NASDAQ:ALTH) was off $0.15 to $1.51 on Friday after EMA's CHMP recommended against conditional approval of Folotyn pralatrexate to treat relapsed or refractory peripheral T cell lymphoma. The MAA was based on data from the single-arm Phase II PROPEL trial, which evaluated a primary endpoint of objective response rate. CHMP said it could not assess Folotyn's benefit because it was not compared with placebo or any other treatment and because the trial did not allow the agency to assess Folotyn's effect on overall survival or progression-free survival.

Allos, which was off $0.04 for the week, said it plans to submit a request for reexamination within two weeks...